Company profile: Emergence Therapeutics
1.1 - Company Overview
Company description
- Provider of novel antibody-drug conjugate (ADC) immunotherapies for high-need cancers, developing programs that combine highly specific antibodies with optimized linker and payload technology; lead program targets Nectin-4, a clinically validated target across a broad range of cancers.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Emergence Therapeutics
CG Oncology
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CG Oncology company profile →
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
Chinook Therapeutics
HQ: Canada
Website
- Description: Provider of precision medicines for kidney diseases, leveraging novel translational platforms and patient stratification tools. Pipeline includes Atrasentan, a selective ETA receptor antagonist in phase 3 for IgA nephropathy and phase 2 for other proteinuric glomerular diseases; Zigakibart (BION-1301), an anti-APRIL monoclonal antibody in phase 3 and phase 1/2 for IgA nephropathy; and CHK-336, an oral LDHA inhibitor in phase 1 for primary and idiopathic hyperoxaluria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chinook Therapeutics company profile →
Abingdon Health
HQ: United Kingdom
Website
- Description: Provider of rapid and near-patient medical diagnostic testing solutions as an innovative, technology-led company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abingdon Health company profile →
Flare Therapeutics
HQ: United States
Website
- Description: Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flare Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Emergence Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Emergence Therapeutics
2.2 - Growth funds investing in similar companies to Emergence Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Emergence Therapeutics
4.2 - Public trading comparable groups for Emergence Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →